QALYs

Dr. William Smith, Pioneer Institute's Visiting Fellow in Life Sciences, spoke about the challenges and opportunities for rare cancer treatments, in a video interview produced by Rare Cancers, a patient group based in Australia, for the November 26th CAN Forum. 

New report asserts that with older americans more vulnerable during the COVID-19 pandemic, all health plans should avoid using the QALY methodology when assessing the value of care for older patients

A new report, "The Legality of QALY under the ADA," outlines several potential legal violations and negative implications for disabled individuals related to the adoption of the QALY approach to drug value assessment, used most prominently by ICER.

Pioneer Institute Discourages Policymakers & Payers from Adopting ICER to Evaluate Rare Disease Treatments Media inquiries: Contact Micaela Dawson, 617-723-2277 ext. 203 or mdawson@pioneerinstitute.org BOSTON, MA – Today, Pioneer Institute released a new report, Looming Challenges for ICER in Assessing the Value of Rare...

This past Monday, Pioneer held the 13th annual Hewitt Healthcare Lecture to honor our longtime chairman (and chairman of Beth Israel Deaconess) Colby Hewitt, Jr. The crowd of 250 enjoyed a substantive and fun night — the two can go together! — at Harvard...

Review methodology could negatively impact elderly, the disabled, cancer patients and those with rare diseases Media inquiries: Contact Micaela Dawson, 617-723-2277 ext. 203 or mdawson@pioneerinstitute.org BOSTON – As states continue to grapple with prescription drug costs, a new Pioneer Institute study lays out...